SCG CELL THERAPY PTE. LTD. Logo Design Contest

SCG CELL THERAPY PTE. LTD. has selected their winning logo design.

For $475 they received 186 designs from 21 different designers from around the world.
Contest
Logo Design Brief Edit  Hide
ZhuangQiushi
Singapore

Slogan

We develop immuno-cancer-therapies.

What We Do

We are a clinical-stage biopharmaceutical company focuses on the development and application of T cell immunotherapies (TCR-T and CAR-T) against cancers that are predominant in Asian population.

Industry

Medical

Top Three Things to Communicate

#1 - The name of the company SCG is the initials of Singapore, China and Germany. It is a joint collaboration between the 3 countries.
#2 - We focus on the T cell immunotherapies, specifically TCR-T and CAR-T technology, which activate the patient’s own immunity system to eliminate the targeted cancer cells.
#3 - We target cancers that are predominant in Asian population.

Our Target Audience:

Our target audiences are our stakeholders including:
1. Cancer hospitals
2. biomedical industries
3. top medical professionals
4. Academics
5. Government Officials
6. Cancer Patients
7. Professional investors – VC, Private Equity fund managers, etc.

Color Preferences

1. Choose colors that are frequently used in Medicine / Healthcare / cancer treatment.

2. Color choice should provide a sense of security and comfort for patients, doctors and other stakeholders.

Our Ideas and Additional Information:

1. The logo should indicate the core technology “cancer immunotherapy”, CAR-T, TCR-T Cell therapies.
2. Asia is the primary market focus.
3. International technology collaboration - Singapore, China and Germany.
4. One look at the logo knows roughly what this company does.

Themes

Feminine
Simple
Colorful
Necessity
Modern
Refined
Secure

Style Inspiration

Applications

Mobile
Desktop
Print
Signs
Clothing

Entries
Order by Ranking Entry Number

Contest Entries

Order by Ranking Entry Number
1st  

Withdrawn

2nd  

Withdrawn

3rd  

Withdrawn

4th  
New  
New  
New  
New  
New  
New  
New  
New  
New  
New  
New  
New  
New  
New  
New  
New  
New  
New  
New  
New  

Withdrawn

New  

Withdrawn

New  

Withdrawn

New  

Withdrawn

New  

Withdrawn

New  

Withdrawn

New  

Withdrawn

New  

Withdrawn

New  

Withdrawn

New  

Withdrawn

New  

Withdrawn

New  

Withdrawn

New  

Withdrawn

New  

Withdrawn

New  

Withdrawn

New  

Withdrawn

New  

Withdrawn

New  

Withdrawn

New  

Withdrawn

New  

Withdrawn

New  

Withdrawn

New  

Withdrawn

New  

Withdrawn

New  

Withdrawn

New  
1 2 3 4